Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067362 | 0.85 | MEN1 (0.59) | KIF11MEN1KMT2ASCN10AKCNH2 | |
| SCHEMBL21101466 | 0.80 | KIF11 (0.54) | KIF11MEN1KMT2ASCN10AMAPT | |
| SCHEMBL5197622 | 0.80 | ALDH1A1 (0.50) | KIF11MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2606005 | 0.80 | KIF11 (0.81) | KIF11SCN10AMAPTKCNH2ALDH1A1 | |
| SCHEMBL29539315 | 0.80 | KIF11 (0.81) | KIF11SCN10AMAPTKCNH2ALDH1A1 | |
| Bromide SCHEMBL30567841 | 0.78 | KIF11 (0.78) | KIF11SCN10AMAPTKCNH2ALDH1A1 | |
| SCHEMBL5193466 | 0.77 | KDM4E (0.53) | MEN1KMT2AMAPTTSHRALDH1A1 | |
| SCHEMBL24943613 | 0.77 | KIF11 (0.51) | KIF11MEN1KMT2ASCN10AMAPT | |
| SCHEMBL31025893 | 0.76 | KIF11 (0.58) | KIF11MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL24839388 | 0.76 | KIF11 (0.68) | KIF11MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-10329282-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | KIF11 758/4885MEN1 1552/4885KMT2A 4097/4885 |
| US-10329282-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | ROCK1, RHOA, ROCK2 | KIF11 1092/4885MEN1 1946/4885KMT2A 3969/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | KIF11 800/4885MEN1 1685/4885KMT2A 3464/4885 |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | SLC10A1, CYP7A1, FABP1 | KIF11 3237/4885MEN1 2920/4885KMT2A 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.